Genomics of Drug Sensitivity in Cancer |
EHT-1864
|
Synonyms |
EHT 1864
|
Targets |
RAC1, RAC2, RAC3
|
Target pathway |
Cytoskeleton
|
PubCHEM ID |
9938202
|
Jsmol |
|
Download molecule |
9938202
|
PUBCHEM IUPAC INCHI |
InChI=1S/C25H27F3N2O4S.2ClH/c26-25(27,28)18-4-5-20-21(14-18)29-7-6-24(20)35-13-3-1-2-10-33-23-17-34-19(15-22(23)31)16-30-8-11-32-12-9-30;;/h4-7,14-15,17H,1-3,8-13,16H2;2*1H
|
Smiles |
Cl.Cl.S(C=1(C=2(C(N=CC=1)=CC(C(F)(F)F)=CC=2)))CCCCCOC=4(C(=O)C=C(CN3(CCOCC3))OC=4)
|
Cluster number |
94
|
calculated LogS |
-5,172
|
Molecular weight |
508,559
|
calculated LogP |
4,0947
|
H-Acceptors |
6
|
H-Donors |
0
|
Ro5 violations |
1
|
Druglikeness |
-10,106
|
DrugScore |
8,27568339344737E-02
|
Mutagenic |
none
|
Tumorigenic |
high
|
Reproductive Effective |
high
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,1791
|
Rat Acute Toxicity |
2,6689
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,7823
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,8283
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-4,3159
|